Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 22 Phantom Stock Units linked to Pfizer common stock on April 30, 2026. Each unit represents one phantom share of common stock and is part of a deferred compensation arrangement, not an open-market stock purchase.
The units were awarded under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash after his separation from service. Following this grant, Bourla holds a total of 760,229 Phantom Stock Units directly under this plan.
Pfizer Inc reports that Vanguard Capital Management beneficially owned 7.51% of Common Stock, representing 427,444,872 shares as of 03/31/2026. The filing lists sole voting power of 58,014,860 shares and sole dispositive power over 427,444,872 shares, with ownership disclosed on behalf of affiliated Vanguard entities.
Gottlieb Scott reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Scott Gottlieb received a new grant of phantom stock units as part of his board compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock at a reference value of $26.67 per unit, bringing his total phantom stock holdings to 57,001.814 units.
According to the footnotes, each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board of Directors, making this a non‑market, compensation-related transaction.
NORA JOHNSON SUZANNE M reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Suzanne M. Nora Johnson received a grant of 7,686.539 Phantom Stock Units on April 23, 2026. Each unit represents one phantom share of Pfizer common stock and was granted at a reference price of $26.67 per unit as deferred director compensation. Following this award, her balance in these units increased to 116,982.649. The units will be settled in cash or common stock, at her election, after she retires from the Board.
LITTMAN DAN R. reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Dan R. Littman received an award of 7,686.539 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of Pfizer common stock and is tied to a reference price of $26.67 per unit.
After this grant, Littman holds a total of 74,533.568 Phantom Stock Units. The units represent deferred director compensation under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at his election, after he retires from the Board.
BLAYLOCK RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Ronald E. Blaylock received a grant of 7,686.539 Phantom Stock Units linked to Pfizer common stock. The units, valued using a reference price of $26.67 per unit, increase his total phantom stock holdings to 84,012.660 units. Each unit represents one phantom share and was granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This award represents deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of phantom stock units as part of his deferred compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock, bringing his total phantom units to 24,391.124 held directly.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or Pfizer common stock, at the director’s election, after he retires from the Board of Directors.
Desmond-Hellmann Susan reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Susan Desmond-Hellmann received a grant of phantom stock units as part of her deferred board compensation. On this Form 4, she was awarded 7,686.539 phantom stock units, each linked to one share of Pfizer common stock. Following the award, she holds 45,635.605 phantom stock units in total. These units are granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at her election, after she retires from the board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 7,686.539 Phantom Stock Units tied to common stock. The units were awarded as director compensation under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and bring his reported phantom unit balance to 161,084.684. Each unit represents one phantom share and will be settled in cash or common stock, at his election, after he retires from the board.
Pfizer Inc. director Shantanu Narayen received a grant of 7,686.539 Phantom Stock Units on common stock-equivalent terms. The award was made at a reference value of $26.67 per unit and is classified as a grant or award acquisition rather than an open-market purchase.
Following this grant, Narayen holds a total of 195,611.680 Phantom Stock Units directly. Each unit represents one phantom share of Pfizer common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation that will be settled in cash or common stock, at Narayen’s election, after his retirement from the Board.